Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Diroximel fumarate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,824Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    GoodRx and Biogen Collaborate to Enhance Enrollment Experience for Providers
    GoodRx and Biogen Collaborate to Enhance Enrollment Experience for Providers

    13 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221013005410/en

    BUSINESSWIRE
    13 Oct 2022
    Share Share
    SMC approves diroximel fumarate as multiple sclerosis treatment
    SMC approves diroximel fumarate as multiple sclerosis treatment

    08 Feb 2022

    // PHARMAFILE

    http://www.pharmafile.com/news/606044/smc-approves-diroximel-fumarate-multiple-sclerosis-treatment

    PHARMAFILE
    08 Feb 2022
    Share Share
    MHRA authorises Vumerity for multiple sclerosis patients
    MHRA authorises Vumerity for multiple sclerosis patients

    19 Nov 2021

    // Lucy Parsons PHARMATIMES

    https://www.pharmatimes.com/news/mhra_authorises_vumerity_for_multiple_sclerosis_patients_1383757

    Lucy Parsons PHARMATIMES
    19 Nov 2021
    Share Share
    European Commission grants marketing authorisation for Vumerity
    European Commission grants marketing authorisation for Vumerity

    17 Nov 2021

    // Anna Begley EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/165570/european-commission-grants-marketing-authorisation-for-vumerity/

    Anna Begley EUROPEANPHARMACEUTICALREVIEW
    17 Nov 2021
    Share Share
    The European Commission Grants Marketing Authorization for VUMERITY®
    The European Commission Grants Marketing Authorization for VUMERITY®

    16 Nov 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/11/16/2335494/0/en/The-European-Commission-Grants-Marketing-Authorization-for-VUMERITY-diroximel-fumarate-as-Oral-Treatment-for-Relapsing-Remitting-Multiple-Sclerosis.html

    GLOBENEWSWIRE
    16 Nov 2021
    Share Share
    New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes
    New Data at ECTRIMS 2021 Highlight Biogen’s Focus on Patient-Centered Outcomes

    13 Oct 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/10/13/2313235/0/en/New-Data-at-ECTRIMS-2021-Highlight-Biogen-s-Focus-on-Patient-Centered-Outcomes-and-Improving-the-MS-Patient-Experience.html

    GLOBENEWSWIRE
    13 Oct 2021
    Share Share